Background: There is no univocal prophylactic regimen to prevent cytomegalovirus (CMV) infection/disease in lung transplantation (LT) recipients. The aim of this study is to evaluate short-term clinical outcomes of a tailored combined CMV management approach. Methods: After 1-year follow up, 43 LT patients receiving combined CMV prophylaxis with antiviral agents and CMV-specific IgG were evaluated in a retrospective observational study. Systemic and lung viral infections were investigated by molecular methods on a total of 1134 whole blood and 167 bronchoalveolar lavage (BAL) and biopsy specimens. CMV immunity was assessed by ELISPOT assay. Clinical and therapeutic data were also evaluated. Results: We found 2/167 cases of CMV pneumonia (1.2%), both in the donor-positive/recipientpositive (D + /R + ) population, and 51/167 cases of CMV pulmonary infection (BAL positivity 30.5%). However, only 32/167 patients (19.1%) were treated due to their weak immunological response at CMV ELISPOT assay. Viremia ⩾100,000 copies/mL occurred in 33/1134 specimens (2.9%). Regarding CMV-serological matching (D/R), the D + /Rpopulation had more CMV viremia episodes (p < 0.05) and fewer viremia-free days (p < 0.001). Conclusions: Compared to previous findings, our study shows a lower incidence of CMV pneumonia and viremia despite the presence of a substantial CMV load. In addition, our findings further confirm the D + /Rgroup to be a high-risk population for CMV viremia. Overall, a good immunological response seems to protect patients from CMV viremia and pneumonia but not from CMV alveolar replication. The reviews of this paper are available via the supplemental material section.
Introduction
Despite significant advances in prevention, cytomegalovirus (CMV) is one of the most significant opportunistic infections occurring after lung transplantation (LT). 1 It can be asymptomatic or manifest as CMV syndrome or tissue-invasive disease. 2, 3 The incidence of CMV infection and disease is highly variable among studies, ranging from 38% to 75% in the absence of any prophylaxis. 4 CMV infection is associated with increased susceptibility to various infections, such as bronchiolitis obliterans syndrome (BOS), increased risk of acute allograft rejection and diminished graft and patient survival. [5] [6] [7] [8] [9] [10] [11] The increased risk of CMV disease and CMV-related mortality appears to be dependent on the CMV status of the donor (D) and/or recipient (R). In this regard, seropositive donor (D + ) and seronegative recipient (R -) have the highest risk of developing these complications. 12, 13 Universal prophylaxis involves the administration of antiviral medication to all patients or to a subset of at-risk patients. 14, 15 Randomized controlled trials and other prospective studies have proposed specific prophylaxis schemes for routine CMV management, with encouraging results in terms of incidence and severity of CMV disease. However, many questions remain unanswered, and a correct strategy to prevent CMV infection/disease in LT has yet to be defined. 16 Even though most anti-CMV therapies rely on intravenous or oral ganciclovir administration, valganciclovir has recently become the first-line therapy due to its excellent oral bioavailability. [17] [18] [19] [20] [21] Indeed, valganciclovir has proven to be far more effective in preventing CMV infection/ disease when given on a long-term basis (i.e. 6-12 rather than ⩽3 months). 8, 22, 23 However, the high variability among LT centers has led to a lack of consensus. 24 In particular, a recent survey has revealed that the majority of LT centers administer CMV-specific hyperimmune globulin in combination with antiviral therapy solely in D + / Rpatients instead of using it as part of universal prophylaxis. 24 Recently, the quantification of the CMV-specific cellular immune response through T-cell ELISPOT has allowed more precise prediction of the individual risk of post-transplantation CMV disease and optimization of prophylaxis. 15 However, only a few studies have assessed the CMV-specific response in LT recipients. In particular, one study has shown a significant correlation between low levels of CMVspecific T-cells and higher frequencies of infectious episodes. 25 Furthermore, others have proposed that an earlier recovery of the immune response may prevent and reduce the duration of CMV infection, avoiding the occurrence of overt disease or its recurrence. [26] [27] [28] [29] The aim of our study was to assess the occurrence and outcomes of CMV infections among LT recipients receiving a combined universal CMV prophylaxis for 12 months post-transplant.
Patients and methods

Study population
All patients receiving LT over a 2-year period (from 1 January 2014 to 31 December 2015) at the Lung Transplant Centre of Turin (Città della Salute e della Scienza di Torino, Italy) were evaluated in a retrospective, observational cohort study. The study was conducted in accordance with the STROBE (strengthening the reporting of observational studies in epidemiology) statement for observational studies. 30 Inclusion and exclusion criteria for study participants were those established by the International Society of Heart and Lung Transplantation (ISHLT) expert panel. 31 This study was approved by our institutional review board (Protocol No. 0004577 -CS/416).
Variables
Patients' were classified into three different LT phases as follows:
( The immune response against CMV was assessed by ELISPOT, as described elsewhere. Patients were classified as responders or nonresponders in the presence of ⩾20 spot-forming units (SFUs) or <20 SFUs, respectively. 35 
Prophylaxis scheme
According to our center practices, the universal combined prophylaxis scheme consists of intravenous administration of ganciclovir, followed by oral valganciclovir at prophylactic dosage. During follow up, we administered oral valganciclovir at prophylactic dosage. [36] [37] [38] [39] [40] [41] The sequential administration scheme was as follows:
• acyclovir (400 mg) twice per day from postoperative day (POD) 5 to POD 14; • intravenous ganciclovir (5 mg/kg) twice per day or valganciclovir (450 mg) twice per day from the POD 15 to POD 45; • CMVIG (0.75 ml/kg) (Cytotect ® Biotest 500 U with the following composition: IgG1 62%, IgG2 34%, IgG3 0.5%, IgG4 3.5%, IgA 5 mg) at PODs 1, 4, 8, 15 and 30 and then monthly at a dose of 0.5 ml/kg; • acyclovir (400 mg) twice per day from POD 46.
Treatment of CMV disease, pneumonia, pulmonary infection and viremia was administered according to international guidelines and recommendations. 14 ELISPOT evaluation played a crucial role in the decision to start the anti-CMV regimen, according to the following criteria:
• CMV pneumonia was always treated regardless of ELISPOT status. • CMV pulmonary asymptomatic infection: no treatment in cases of patient responders with ⩽10 CMV cells isolated from BAL or with ⩽10,000 CMV-DNA copies/ml BAL; treatment in cases of patient responders with increased number of CMV cells isolated from BAL or increased CMV-DNA copies in BAL with respect to a previous untreated infection; treatment in the absence of ELISPOT evaluation.
• CMV viremia: no treatment in responders with CMV-DNA viremia ⩽100,000/ml (i.e. 39,000 UI/ml).
Immunosuppressive scheme
For induction of immunosuppression, we used antithymocyte globulins (Fresenius, Munich, Germany). The immunosuppressive regimen consisted of a triple-drug therapy with one calcineurin inhibitor (i.e. cyclosporine or tacrolimus), one antiproliferative agent (i.e. azathioprine, mycophenolate or everolimus) and corticosteroids. In cases of first asymptomatic pulmonary infection or CMV viremia, the immunosuppressive regimen was maintained. In cases of recurrence of CMV infections, we preferentially used everolimus due to its effects on CMV. 39, 40 Statistical analysis For statistical analysis, we used Chi-square test for categorical data and two-sided Student's t test and ANOVA for continuous variables. The Kaplan-Meier curves test was used to compare disease-free days among different patient groups. Statistical analysis was performed using Prism 7.0 (GraphPad, La Jolla, CA, USA).
Results
Baseline characteristics
Forty-three patients were included in this study. Demographic and clinical features are shown in Table 1 . Considering all the different study phases, we collected a total of 167 BAL and 167 TBLB specimens and 1134 whole blood samples. Overall 1-year survival was 90.7%.
With regard to the humoral response against CMV, 33/43 (77%) patients exhibited IgG positivity with a mean titer of 215 AU/ml. In our cohort, 27/43 (63%) of patients were D + /R + , 9/43 (21%) D + /R -, 6/43 (14%) D -/R + and 1/43 (2%) D -/R - (Table 1) .
CMV pneumonia
Overall, we recorded two cases of CMV pneumonia, accounting for an incidence of 1.2% (2/167) and a prevalence of 4.7% among patients (2/43). Both cases were D + /R + patients. (Table 3 ).
Discussion
Cytomegalovirus infection can have negative health consequences for LT recipients, for whom in the past decades a number of prophylactic schemes based on valganciclovir have been developed. [42] [43] [44] In addition to valganciclovir, current prophylactic regimens include ganciclovir and CMV hyperimmune globulin given for different lengths of time, with variable efficacy rates against CMV infection and disease. 14, 24 In this study, we have evaluated the results of a universal combined prophylaxis scheme for CMV in LT patients. In our cohort, incidence of CMV pneumonia, infection and asymptomatic viremia were similar to or even lower than those recorded in studies addressing longer courses of antiviral drugs, but with our protocol we administered a much lower drug load. 23 We also observed fewer ganciclovir/valganciclovir therapy discontinuation episodes due to adverse drug effects. D + /R + patients had a higher incidence of pulmonary infection, albeit not significant, whereas the D + Rpopulation displayed a higher risk of developing significant CMV viremia. High-titer CMV IgG provided a passive CMVspecific immunity and seemed to play an important role in immunomodulation of specific responses, showing an antiviral effect similar to that of antivirals. 45 Although the use of these preparations seems to be effective in reducing CMV pneumonia and to have some effect on acute rejection, the high variability in dosages and administration schedules has undoubtedly contributed to downplaying their evidence-based effectiveness despite the existence of many single-center or anecdotal studies. 36, 37 The main point of discussion of our results are the following
CMV pneumonia
The incidence of CMV disease and pneumonia is highly variable among studies, ranging from 4% to 32%, and it is related to the duration of prophylaxis. 13, 23 Other LT centers adopted schemes with different treatment durations, depending on the D/R status. 13 In Schoeppler and colleagues' study, 46 the authors reported an almost doubled risk of CMV disease in D + /Rversus D + /R + recipients (19.5% versus 10.7%, respectively). In our scheme, given a lower incidence of CMV pneumonia reported in previous studies, 38, 39 CMV-specific hyperimmune globulins were administered regardless of D/R status. Fittingly, our incidence of CMV pneumonia was 1% on follow-up BAL and TBLB specimens, which was even lower than that reported in the literature despite the shorter antiviral regimen. Both of our pneumonia cases were among the most represented D + /R + population and occurred within 30 days of transplant. Even though the D + /R + population has been shown to have a lower risk of CMV disease and pneumonia compared to the D + /Rone, it is likely that the strong immunosuppressive regimen in the first post-LT month might have exposed the patients to a higher risk, regardless of their CMV serostatus.
CMV pulmonary infections
In the literature, the incidence of pulmonary infection is highly variable, depending on which of the various definitions is being adopted. In our BAL specimens we found a 30% incidence of pulmonary infection, which is higher than that reported in other studies. In particular, we show that 69% of these patients experienced at least one episode during the first year, recorded over five follow-up BAL samplings per patient. The D + /R + group, the most represented population in our study, had the highest number of asymptomatic infections. On the other hand, D + /Rpatients showed the highest prevalence (100%) among all groups, which makes this population the 'at-risk population'. These findings differ from those reported by previous studies, where the incidence of asymptomatic infection was significantly lower, especially in the presence of antiviral prophylaxis. 11, 23 Conversely, the incidence increased (ranging from 10% to 64%) when a shorter prophylaxis course was carried out, 11, 23 and the survival rate was lower compared to those patients who never experienced a CMV infection (55% versus 84%). 11 In our study, D + /Rpatients had a higher incidence of asymptomatic pulmonary infection, albeit not statistically significant, but none of them exhibited invasive disease (e.g. CMV pneumonia), indicating the appropriateness and effectiveness of the prophylactic strategy. Incidence was higher during the first month after LT, slowly decreasing during the subsequent months. This phenomenon might be in part due to the immunosuppressive load received by the patient during the first period.
CMV viremia
From our data, the incidence of CMV viremia is considerably lower than that of pulmonary infection, as the CMV monitoring strategy is expressly aimed at limiting the infection to the alveolar environment, the natural replication domain of the virus, thereby preventing the development of systemic (blood) disease. Although we found a lower number of cases of CMV viremia compared to those of pulmonary infection, 44% of patients of our population experienced at least one episode of significant CMV viremia, whereas only 30% of patients had asymptomatic pulmonary infection. Once again, the incidence reported in the literature is lower, ranging from 21%, in the case of 6-12 months of prophylaxis, 11 to 12% in the case of indefinite prophylaxis, 16 even though the CMV-DNA copy threshold is variable among studies. Nevertheless, our data confirm the D + /Rpopulation to be at higher risk of developing CMV viremia during the first year, with a lower number of viremia-free days. 11, 16 Antiviral treatment In our cohort, all patients with CMV pneumonia received antiviral treatment, whereas only 62% of cases with asymptomatic CMV pulmonary infection were treated. The therapeutic management was based on the recipient's serostatus, immunological response at ELISPOT assay, ongoing prophylactic treatment and previous episodes of CMV infection. If we only take into account the treated patients, because of an unfavorable balance load/immunity, the incidence of asymptomatic CMV pulmonary infections was 19% (32/167), in good agreement with previous studies assessing LT recipients treated with longer ganciclovir/valganciclovir prophylactic regimens. 11, 16, 23 Due to the shorter duration of the ganciclovir/valganciclovir prophylactic scheme, the discontinuation rate in our cohort was only 9%, which was significantly lower than what has been previously reported. 16 Moreover, 19% of our patients had asymptomatic pulmonary infection during the first (and unique) month of valganciclovir therapy, confirming the relative inefficacy of valganciclovir prophylaxis in preventing alveolar viral replication.
CMV ELISPOT in clinical practice
The CMV ELISPOT assay can predict the protection from CMV disease and viremia by estimating T-cell responsiveness; 33, 34, 47, 48 thus, the evaluation of the CMV-specific T-cell response by ELISPOT has played a key role in our tailored approach. Indeed, the detection of an immunological response determined our decision to monitor CMV replication.
ELISPOT assay quantifies T-cells producing IFN-γ in response to CMV, albeit not distinguishing the CD4 + T-cell response from that of CD8 + T-cells. 14 High dosages of immunosuppressive drugs administered after LT can result in dysfunction and progressive loss of the CD4 +specific response to CMV, 49 which in turn favors the recurrence of infections and clinical manifestations of CMV replication. 49 This appears to be critical during the first months after LT when the susceptibility to CMV infections is higher and the immune response can be measured. Our study showing two cases of pneumonia occurring during the first month after LT in two D + /R + responders (notably low-risk patients) further corroborates the higher susceptibility to CMV infections soon after LT. Consistently, after this critical period we did not record any CMV pneumonia episodes in our cohort.
Remarkably, all responders at ELISPOT assay maintained their status throughout the whole observation period. Most nonresponders (12/13, 92.3%) switched to a responder status because of either immunosuppression modulation or, in case of the Rgroup, new infection. In this regard it is important to mention that constant circulating levels of CMV-DNA are necessary for the correct stimulation of an immunological response. Thus, immediate antiviral therapy, knocking down CMV-DNA circulating levels, would hamper the CD4 + -specific response, explaining the higher incidence of infective episodes and viral reactivations in nonresponders. 34, 36 In our cohort, the presence of a CMV-specific immune response appeared to protect patients from significant CMV viremia but not from CMV asymptomatic pulmonary infections in natural CMV replication sites.
In conclusion, our data give rise to some reasonable clinical interpretations. First and foremost, our 'low drug load combined prophylaxis' resulted in a low number of CMV pneumonia cases and treatments for both asymptomatic CMV pulmonary infections and significant viremia. In addition, our prophylaxis allows the development of natural immunity thanks to a low continuous exposure to CMV, while simultaneously preventing CMV invasive disease. Lastly, ELISPOT CMV assay is an essential tool for making the correct therapeutic choice against CMV infection, especially when dealing with an antiviral approach, given that positivity is related to lower CMV blood replication.
Further randomized studies exploring different prophylactic schemes and alternative DNA cutoff levels for preemptive therapy are clearly needed to evaluate the best balance between CMV infection and treatment costs, in terms of clinical outcome, drug-related side effects and economical load. 
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